文献速递淋巴瘤

Idelalisib联合利妥昔单抗治疗慢性淋巴细胞白血病的英国和爱尔兰回顾性研究

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
PubMed 文献 · Br J Haematol · 2021-06-14

RETRO-idel是一项方案导向的回顾性研究,纳入110例接受Idelalisib联合利妥昔单抗治疗的慢性淋巴细胞白血病患者(27例一线治疗)。

核心结论

  • IDL-R在常规实践中的疗效数据明确,未发现新的安全性信号,但需仔细管理已知毒性。

研究设计与样本

  • RETRO-idel为方案导向的回顾性观察研究,纳入110例接受IDL-R治疗的CLL患者,其中一线治疗27例。

临床怎么用

  • IDL-R可用于CLL一线及复发/难治治疗,但需密切监测并及时处理感染、腹泻和结肠炎等毒性。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was a protocol-led, retrospective study of 110 patients [n = 27 front-line (1L)] who received IDL-R. The primary end-point was clinical overall response rate (ORR). The median (range) follow-up of the whole cohort was 30·2 (0·1-51·9) months. The median (range) age was 72 (48-89) years. Tumour protein p53-disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention-to-treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event-free survival (mEFS) was 20·3 months and time-to-next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3-year overall survival was 56·1% (95% confidence interval 45·7-65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front-line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea in 30·9% (Grade ≥3, 6·4%), and colitis in 9·1% (Grade ≥3, 5·5%). Overall, these data describe clear efficacy for IDL-R in routine practice. No new safety signals were identified, although careful management of known toxicities is required.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Eyre TA, Preston G, Kagdi H, et al. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). Br J Haematol. 2021. PMID: 34121184. doi:10.1111/bjh.17475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。